Peptide mapping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。
常规纯度与身份确认依赖反相高效液相色谱，并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成，肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同，因此各实验室报告的纯度数值不宜直接横向比较。
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
| Property | Value | Notes |
|---|---|---|
| 外观 | 白色至类白色粉末 | 常见于冻干制剂 |
| 溶解度 | 易溶于水 | 在极性溶剂中一般也可溶 |
| 建议储存温度 | -20 °C | 冻干粉，避光密封 |
| 常见分析手段 | 反相高效液相色谱 | 常与质谱联用 |
| 主要降解路径 | 水解与氧化 | 溶液状态更显著 |
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
稳定性主要由水解与氧化两条路径支配。肽键在中性或弱酸性条件下相对稳定，遇到强碱或长时间高温则明显断裂；甲硫氨酸侧链容易被氧化成亚砜，使主峰前移并拉低实际含量。金属离子、光照和反复冻融会进一步促进降解或聚集。冻干粉在低温避光条件下可存放较长时间，配制后的水溶液通常需要冷藏并尽快用完。
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
== Structural studies == As of late 2007, 7 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1KHH, PDB: 1P1B, PDB: 1P1C, PDB: 1XCJ, PDB: 1XCL, PDB: 1ZX0, and PDB: 2BLN.
The Doobie Brothers are an American rock band formed in San Jose, California, in 1970. Known for their flexibility in performing across numerous genres and their vocal harmonies, the band has been active for over five decades, with their greatest success taking place in the 1970s. The group's current lineup consists of founding members Tom Johnston (guitars, keyboards, harmonica, vocals) and Patrick Simmons (guitars, banjo, recorder, vocals), alongside Michael McDonald (keyboards, synthesizers, mandolin, vocals) and John McFee (guitars, pedal steel guitar, mandolin, banjo, violin, cello, harmonica, vocals), and touring musicians including John Cowan (bass, vocals), Marc Russo (saxophones), Ed Toth (drums), and Marc Quiñones (percussion, backing vocals). Long-serving former members include guitarist Jeff "Skunk" Baxter, bassist Tiran Porter, and drummers John Hartman, Michael Hossack, and Keith Knudsen. Johnston provided the lead vocals from 1970 to 1975, when they featured a mainstream rock sound with elements of folk, country and R&B. McDonald joined the band in 1975 as a keyboardist and additional lead vocalist, to give some relief to Johnston, who was suffering health problems at the time. McDonald's interest in soul music introduced a new sound to the band. Johnston, Simmons, Porter, and McDonald performed together as lead vocalists for one album, Takin' It to the Streets, before Johnston left in 1977.
==== 1.D Non-ribosomally synthesized channels ==== 1.D.1 The Gramicidin A Channel Family 1.D.2 The Channel-forming Syringomycin Family 1.D.3 The Channel-Forming Syringopeptin Family 1.D.4 The Tolaasin Channel-forming Family 1.D.5 The Alamethicin or Peptaibol Antibiotic Channel-forming Family 1.D.6 The Complexed Poly 3-Hydroxybutyrate Ca2+ Channel (cPHB-CC) Family 1.D.7 The Beticolin Family 1.D.8 The Saponin Family 1.D.9 The Polyglutamine Ion Channel (PG-IC) Family 1.D.10 The Ceramide-forming Channel Family 1.D.11 The Surfactin Family 1.D.12 The Beauvericin (Beauvericin) Family 1.D.13 DNA-delivery Amphipathic Peptide Antibiotics (DAPA) 1.D.14 The Synthetic Leu/Ser Amphipathic Channel-forming Peptide (l/S-SCP) Family 1.D.15 The Daptomycin (Daptomycin) Family 1.D.16 The Synthetic Amphipathic Pore-forming Heptapeptide (SAPH) Family 1.D.17 Combinatorially-designed, Pore-forming, β-sheet Peptide Family 1.D.18 The Pore-forming Guanosine-Bile Acid Conjugate Family 1.D.19 Ca2+ Channel-forming Drug, Digitoxin Family 1.D.20 The Pore-forming Polyene Macrolide Antibiotic/fungal Agent (PMAA) Family 1.D.21 The Lipid Nanopore (LipNP) Family 1.D.22 The Proton-Translocating Carotenoid Pigment, Zeaxanthin Family 1.D.23 Phenylene Ethynylene Pore-forming Antimicrobial (PEPA) Family 1.D.24 The Marine Sponge Polytheonamide B (pTB) Family 1.D.25 The Arylamine Foldamer (AAF) Family 1.D.26 The Dihydrodehydrodiconiferyl alcohol 9'-O-β-D-glucoside (DDDC9G) Family 1.D.27 The Thiourea isosteres Family 1.D.28 The Lipopeptaibol Family 1.D.29 The Macrocyclic Oligocholate Family 1.D.30 The Artificial Hydrazide-appended pillar[5]arene Channels (HAPA-C) Family 1.D.31 The Amphotericin B Family 1.D.32 The Pore-forming Novicidin Family 1.D.33 The Channel-forming Polytheonamide B Family 1.D.34 The Channel-forming Oligoester Bolaamphiphiles 1.D.35 The Pore-forming cyclic Lipodepsipeptide Family 1.D.36 The Oligobornene Ion Channel Family 1.D.37 The Hibicuslide C Family 1.D.38 The Cyclic Peptide Nanotube (cPepNT) Family 1.D.39 The Light-controlled Azobenzene-based Amphiphilic Molecular Ion Channel (AAM-IC) Family 1.D.40 The Protein-induced Lipid Toroidal Pore Family 1.D.41 The Sprotetonate-type Ionophore (Spirohexanolide) Family 1.D.42 The Phe-Arg Tripeptide-Pillar[5]Arene Channel (TPPA-C) Family 1.D.43 The Triazole-tailored Guanosine Dinucleoside Channel (TT-GDN-C) Family 1.D.44 The Synthetic Ion Channel with Redox-active Ferrocene (ICRF) Family 1.D.45 The Sonoporation and Electroporation Membrane Pore (SEMP) Family 1.D.46 The DNA Nanopore (DnaNP) Family 1.D.47 The Pore-forming Synthetic Cyclic Peptide (PSCP) Family 1.D.48 The Pore-forming Syringomycin E Family 1.D.49 The Transmembrane Carotenoid Radical Channel (CRC) Family 1.D.50 The Amphiphilic bis-Catechol Anion Transporter (AC-AT) Family 1.D.51 The Protein Nanopore (ProNP) Family 1.D.52 The Aromatic Oligoamide Macrocycle Nanopore (OmnNP) Family 1.D.53 The alpha, gamma-Peptide Nanotube (a,gPepNT) Family 1.D.54 The potassium-selective Hexyl-Benzoureido-15-Crown-5-Ether Ion Channel (HBEC) Family 1.D.55 The Porphyrin-based Nanopore (PorNP) Family 1.D.56 The Alpha-Aminoisobutyrate (Aib) Oligomeric Nanopore (AibNP) Family 1.D.57 The Lipid Electro-Pore (LEP) Family 1.D.58 The Anion Transporting Prodigiosene (Prodigiosene) Family 1.D.59 The Anion Transporting Perenosin (Perenosin) Family 1.D.60 The Alpha,Gamma-Cyclic Peptide (AGCP) Family 1.D.61 The Anionophoric 2,6-Bis(Benzimidazol-2-yl)Pyridine (ABBP) Family 1.D.62 The Bis-Triazolyl DiGuanosine Derivative Channel-forming (TDG) Family 1.D.63 The Peptide-based Nanopore (PepNP) Family 1.D.64 The Carbon Nanotube (CarNT) Family 1.D.65 The Pore-forming Amphidinol (Amphidinol) Family 1.D.66 The Helical Macromolecule Nanopore (HmmNP) Family 1.D.67 The Crown Ether-modified Helical Peptide Ion Channel (CEHP) Family 1.D.68 The Pore-forming Pleuronic Block Polymer (PPBP) Family 1.D.69 The Conical Nanopore (ConNP) Family 1.D.70 The Metallic (Au/Ag/Pt/graphene) Nanopore (MetNP) Family 1.D.71 The Synthetic TP359 Peptide (TP359) Family 1.D.72 The Chloride Carrier Triazine-based Tripodal Receptor (CCTTR) Family 1.D.73 The Mesoporous Silica Nanopore (SilNP) Family 1.D.74 The Stimulus-responsive Synthetic Rigid p-Octiphenyl Stave Pore (SSROP) Family
N-Formylmethionyl-leucyl-phenylalanine (fMLF, fMLP or N-formyl-met-leu-phe) is an N-formylated tripeptide and sometimes simply referred to as chemotactic peptide is a potent polymorphonuclear leukocyte (PMN) chemotactic factor and is also a macrophage activator. fMLF is the prototypical representative of the N-formylated oligopeptide family of chemotactic factors. These oligopeptides are known to be, or mimic the actions of, the N-formyl oligopeptides that are (a) released by tissue bacteria, (b) attract and activate circulating blood leukocytes by binding to specific G protein coupled receptors on these cells, and (c) thereby direct the inflammatory response to sites of bacterial invasion. fMLF is involved in the innate immunity mechanism for host defense against pathogens. fMLF led to the first discovery of a leukocyte receptor for a chemotactic factor, defined three different types of fMLF receptors that have complementary and/or opposing effects on inflammatory responses as well as many other activities, and helped define the stimulus-response coupling mechanisms by which diverse chemotactic factors and their G protein coupled receptors induce cellular function.
Sources: en.wikipedia.org
== History == Studies in the early 1960s showed that administration of α-MSH caused sexual arousal in rats, sparking interest in α-MSH. In the 1980s, scientists at University of Arizona began developing α-MSH and analogs as potential sunless tanning agents. They synthesized and tested several analogs, including peptides they subsequently named melanotan-I and melanotan II. Very early in the process, one of the scientists, Mac Hadley, was conducting self-experiments with melanotan II. He mistakenly injected himself with twice the intended dose and experienced an eight-hour erection, along with nausea and vomiting. To pursue the tanning agent, melanotan-I was licensed by Competitive Technologies, a technology transfer company operating on behalf of University of Arizona, to an Australian startup called Epitan, which changed its name to Clinuvel in 2006. To pursue the sexual dysfunction agent, melanotan II was licensed by Competitive Technologies to Palatin Technologies. Palatin ceased development of melanotan II in 2000, and synthesized, patented, and began to develop bremelanotide, a likely metabolite of melanotan II that differs from melanotan II in that it has a hydroxyl group where melanotan II has an amide. Competitive Technologies sued Palatin for breach of contract and to try to claim ownership of bremelanotide; the parties settled in 2008, with Palatin retaining rights to bremelanotide, returning rights to melanotan II to Competitive Technologies, and paying $800,000.
On 20 September 2014, while speaking to party workers in Multan, Bhutto Zardari said, "I will take back Kashmir, all of it, and I will not leave behind a single inch of it because, like the other provinces, it belongs to Pakistan." The statement was to be the first marking his stance on the Kashmir issue and remarked upon widely in local and international media. On 6 February 2019, Bhutto Zardari met with the Kashmir Council in Washington to express solidarity with the people of Kashmir. During the meeting, he assured the delegation that he would continue to raise his voice against the brutalities of Indian forces against innocent and unarmed Kashmiri people at every available forum both nationally and internationally. He said that loyalty to the cause of Kashmir was in his blood and he would stand with the people of Indian-administered Kashmir in their just struggle for the right to self-determination and freedom from illegal and immoral Indian occupation. On 15 October 2022, after U.S. President Joe Biden referred to Pakistan as "one of the most dangerous nations in the world" and as a carrier of "nuclear weapons without any cohesion" at a Democratic Party fundraiser in California, Bhutto Zardari summoned American diplomat Donald Blome to the Ministry of Foreign Affairs and demanded an explanation as well as called for an official démarche.
Fever is an important metric for the diagnosis of disease in domestic animals. The body temperature of animals, which is taken rectally, is different from one species to another. For example, a horse is said to have a fever above 101 °F (38.3 °C). In species that allow the body to have a wide range of "normal" temperatures, such as camels, whose body temperature varies as the environmental temperature varies, the body temperature which constitutes a febrile state differs depending on the environmental temperature. Fever can also be behaviorally induced by invertebrates that do not have immune-system based fever. For instance, some species of grasshopper will thermoregulate to achieve body temperatures that are 2–5 °C higher than normal to inhibit the growth of fungal pathogens such as Beauveria bassiana and Metarhizium acridum. Honeybee colonies are also able to induce a fever in response to a fungal parasite Ascosphaera apis.
Sources: en.wikipedia.org
一般不建议常温长期保存。多数说明指向 -20 °C 冷冻避光。常温运输通常被视为短期可接受，但会加快降解风险。
公开资料对此没有统一答案。普遍建议现配现用，或冷藏并在数日内用完。含甲硫氨酸的序列更易氧化，放置时间越长风险越高。
反相高效液相色谱是最常用的手段，配合质谱确认分子量。氨基酸组成分析和肽图分析可补充序列层面的验证。
Reversed-phase high-performance liquid chromatography is the standard method, with detection in the ultraviolet range. Peak area percentage yields a purity figure for the main component. Mass spectrometry is normally run alongside to confirm molecular identity.